Literature DB >> 26481322

Post-trial obligations in the Declaration of Helsinki 2013: classification, reconstruction and interpretation.

Ignacio Mastroleo.   

Abstract

The general aim of this article is to give a critical interpretation of post-trial obligations towards individual research participants in the Declaration of Helsinki 2013. Transitioning research participants to the appropriate health care when a research study ends is a global problem. The publication of a new version of the Declaration of Helsinki is a great opportunity to discuss it. In my view, the Declaration of Helsinki 2013 identifies at least two clearly different types of post-trial obligations, specifically, access to care after research and access to information after research. The agents entitled to receive post-trial access are the individual participants in research studies. The Declaration identifies the sponsors, researchers and host country governments as the main agents responsible for complying with the post-trial obligations mentioned above. To justify this interpretation of post-trial obligations, I first introduce a classification of post-trial obligations and illustrate its application with examples from post-trial ethics literature. I then make a brief reconstruction of the formulations of post-trial obligations of the Declaration of Helsinki from 2000 to 2008 to correlate the changes with some of the most salient ethical arguments. Finally I advance a critical interpretation of the latest formulation of post-trial obligations. I defend the view that paragraph 34 of 'Post-trial provisions' is an improved formulation by comparison with earlier versions, especially for identifying responsible agents and abandoning ambiguous 'fair benefit' language. However, I criticize the disappearance of 'access to other appropriate care' present in the Declaration since 2004 and the narrow scope given to obligations of access to information after research.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  benefit sharing; health care after research; information after research; moral obligation; post-trial access ethics; research ethics; right to health

Mesh:

Year:  2015        PMID: 26481322     DOI: 10.1111/dewb.12099

Source DB:  PubMed          Journal:  Dev World Bioeth        ISSN: 1471-8731            Impact factor:   2.294


  13 in total

Review 1.  Human dignity as a basis for providing post-trial access to healthcare for research participants: a South African perspective.

Authors:  Pamela Andanda; Jane Wathuta
Journal:  Med Health Care Philos       Date:  2018-03

2.  Correlations of IGF-1R and COX-2 Expressions with Ras and BRAF Genetic Mutations, Clinicopathological Features and Prognosis of Colorectal Cancer Patients.

Authors:  Mei Jin; Zi-Wen Long; Jing Yang; Xiang Lin
Journal:  Pathol Oncol Res       Date:  2017-02-10       Impact factor: 3.201

3.  MicroRNA-21 promotes cell proliferation, migration, and resistance to apoptosis through PTEN/PI3K/AKT signaling pathway in esophageal cancer.

Authors:  Yan-Ran Wu; Hai-Jun Qi; Dan-Fang Deng; Ying-Ying Luo; Sheng-Lan Yang
Journal:  Tumour Biol       Date:  2016-05-17

4.  Reduced expression and prognostic implication of inhibitor of growth 4 in human osteosarcoma.

Authors:  Dahang Zhao; Xiangjie Liu; Yunge Zhang; Zhaoming Ding; Feng Dong; Hongwei Xu; Baoxin Wang; Wenbo Wang
Journal:  Oncol Lett       Date:  2016-03-09       Impact factor: 2.967

5.  Piezo1 protein induces the apoptosis of human osteoarthritis-derived chondrocytes by activating caspase-12, the signaling marker of ER stress.

Authors:  Xiao-Fei Li; Zhao Zhang; Zhu-Ke Chen; Zhao-Wei Cui; Hai-Ning Zhang
Journal:  Int J Mol Med       Date:  2017-07-19       Impact factor: 4.101

6.  Plasma miR-21 expression: an indicator for the severity of Type 2 diabetes with diabetic retinopathy.

Authors:  Qi Jiang; Xue-Man Lyu; Yi Yuan; Ling Wang
Journal:  Biosci Rep       Date:  2017-03-27       Impact factor: 3.840

7.  MicroRNA-126 affects rheumatoid arthritis synovial fibroblast proliferation and apoptosis by targeting PIK3R2 and regulating PI3K-AKT signal pathway.

Authors:  Yuan Qu; Jing Wu; Jia-Xin Deng; Yu-Ping Zhang; Wan-Yi Liang; Zhen-Lan Jiang; Qing-Hong Yu; Juan Li
Journal:  Oncotarget       Date:  2016-11-08

Review 8.  Biobanking in health care: evolution and future directions.

Authors:  Luigi Coppola; Alessandra Cianflone; Anna Maria Grimaldi; Mariarosaria Incoronato; Paolo Bevilacqua; Francesco Messina; Simona Baselice; Andrea Soricelli; Peppino Mirabelli; Marco Salvatore
Journal:  J Transl Med       Date:  2019-05-22       Impact factor: 5.531

Review 9.  Plants and Natural Products with Activity against Various Types of Coronaviruses: A Review with Focus on SARS-CoV-2.

Authors:  Susana A Llivisaca-Contreras; Jaime Naranjo-Morán; Andrea Pino-Acosta; Luc Pieters; Wim Vanden Berghe; Patricia Manzano; Jeffrey Vargas-Pérez; Fabian León-Tamariz; Juan M Cevallos-Cevallos
Journal:  Molecules       Date:  2021-07-05       Impact factor: 4.411

10.  Expression of microRNA-155-5p in patients with refractory diabetic macular edema and its regulatory mechanism.

Authors:  Junwen He; Rui Zhang; Shan Wang; Lu Xie; Chengfeng Yu; Tao Xu; Yanzi Li; Tao Yan
Journal:  Exp Ther Med       Date:  2021-07-08       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.